Close Menu


Using arrays to screen embryos during an in vitro fertilization cycle can improve pregnancy rates, according to a new study.

By Justin Petrone
British array firm BlueGnome this month relocated to new headquarters to keep pace with growth that has seen it double most of activities in the past year.

Cambridge, UK-based BlueGnome made the acquisition to carve out a bigger piece of the pre-implantation, genetic-diagnostic market. The firm "aims to address diagnosis of single-gene disorders using SNP-array technology," according to its CEO.

The new firm, founded to take advantage of a "rapidly growing" market for pre-implantation genetic screening services, will directly offer BlueGnome's 24Sure platform to in vitro fertilization centers in Europe.

The results not only have the potential to improve the chances of pregnancy for couples undergoing IVF, but also point toward opportunities for research and diagnostic testing of single cancer cells and stem cells, according to a Rubicon official.

The company will use the money to accelerate the global launch of its metabolomics-based procedure for enhancing in vitro fertilization outcomes.


The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.